COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

5.02%

Increased from previous period

Growth of 5.02% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

5.84%

Increased from previous period

Cost growth of 5.84% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

1.81%

Increased from previous period

Growth of 1.81% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

-3.06%

Decreased from previous period

Margin decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

-20.03%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

0.69%

Decreased from previous period

Operating expenses growth 1.25-1.5x Healthcare median of 0.54%. Guy Spier would scrutinize spending.

Total Costs & Expenses Growth

4.95%

Increased from previous period

Total costs growth exceeding 1.5x Healthcare median of 0.78%. Jim Chanos would check for waste.

Interest Expense Growth

No Data

No Data available this quarter, please select a different quarter.

Depreciation & Amortization Growth

-19.59%

Decreased from previous period

D&A reduction while Healthcare median is 1.05%. Seth Klarman would investigate efficiency.

EBITDA Growth

2.53%

Decreased from previous period

EBITDA growth exceeding 1.5x Healthcare median of 0.37%. Joel Greenblatt would investigate advantages.

EBITDA Margin Growth

-2.37%

Decreased from previous period

EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

6.86%

Increased from previous period

Income change of 6.86% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

1.75%

Increased from previous period

Margin change of 1.75% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-31.30%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

2.14%

Increased from previous period

Income change of 2.14% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

-2.75%

Increased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

2.39%

Increased from previous period

Tax expense change of 2.39% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

1.99%

Increased from previous period

Income change of 1.99% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

-2.89%

Increased from previous period

Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

2.00%

Increased from previous period

EPS growth 50-75% of Healthcare median of 3.19%. Guy Spier would scrutinize operations.

Diluted EPS Growth

2.00%

Increased from previous period

Diluted EPS growth 50-75% of Healthcare median of 3.13%. Guy Spier would scrutinize operations.

Share Count Growth (Basic)

No Data

No Data available this quarter, please select a different quarter.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

5.02%

Increased from previous period

Growth of 5.02% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

5.84%

Increased from previous period

Cost growth of 5.84% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

1.81%

Increased from previous period

Growth of 1.81% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

-3.06%

Decreased from previous period

Margin decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

-20.03%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

0.69%

Decreased from previous period

Operating expenses growth 1.25-1.5x Healthcare median of 0.54%. Guy Spier would scrutinize spending.

Total Costs & Expenses Growth

4.95%

Increased from previous period

Total costs growth exceeding 1.5x Healthcare median of 0.78%. Jim Chanos would check for waste.

Interest Expense Growth

No Data

No Data available this quarter, please select a different quarter.

Depreciation & Amortization Growth

-19.59%

Decreased from previous period

D&A reduction while Healthcare median is 1.05%. Seth Klarman would investigate efficiency.

EBITDA Growth

2.53%

Decreased from previous period

EBITDA growth exceeding 1.5x Healthcare median of 0.37%. Joel Greenblatt would investigate advantages.

EBITDA Margin Growth

-2.37%

Decreased from previous period

EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Operating Income Growth

6.86%

Increased from previous period

Income change of 6.86% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

1.75%

Increased from previous period

Margin change of 1.75% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-31.30%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

2.14%

Increased from previous period

Income change of 2.14% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

-2.75%

Increased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

2.39%

Increased from previous period

Tax expense change of 2.39% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

1.99%

Increased from previous period

Income change of 1.99% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

-2.89%

Increased from previous period

Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

EPS Growth

2.00%

Increased from previous period

EPS growth 50-75% of Healthcare median of 3.19%. Guy Spier would scrutinize operations.

Diluted EPS Growth

2.00%

Increased from previous period

Diluted EPS growth 50-75% of Healthcare median of 3.13%. Guy Spier would scrutinize operations.

Share Count Growth (Basic)

No Data

No Data available this quarter, please select a different quarter.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric: